Type I interferon regulation of natural killer cell function in primary and secondary infections

References

• Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 16(2), 216–229 (1975).
   PubMed Web of Science ®Google Scholar
• Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16(2), 230–239 (1975).
   PubMed Web of Science ®Google Scholar
• Lanier L, Phillips J, Hackett J, Tutt M, Kumar V. Natural killer cells: definition of a cell type rather than a function. J. Immunol 137(9), 2735–2739 (1986).
   PubMed Web of Science ®Google Scholar
• Ennis F, Beare AS, Riley D et al. Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 318(8252), 891–893 (1981).
   Google Scholar
• Bustamante J, Boisson-Dupuis S, Jouanguy E et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr. Opin. Immunol. 20(1), 39 (2008).
   PubMed Web of Science ®Google Scholar
• Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320(26), 1731–1735 (1989).
   PubMed Web of Science ®Google Scholar
• Orange JS. Human natural killer cell deficiencies. Curr. Opin. Allergy Clin. Immuno. 6(6), 399–409 (2006).
   PubMed Web of Science ®Google Scholar
• Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microb. Infect. 4(15), 1545–1558 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 5(5), 363–374 (2005).
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14(1), 619–648 (1996).
   PubMed Web of Science ®Google Scholar
• Long EO. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17(1), 875–904 (1999).
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9(5), 495–502 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106(6), 1915–1919 (2009).
   PubMed Web of Science ®Google Scholar
• Swann JB, Hayakawa Y, Zerafa N et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178(12), 7540–7549 (2007).
   PubMed Web of Science ®Google Scholar
• Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunol. 128(2), 151–163 (2009).
   PubMed Web of Science ®Google Scholar
• Rasmussen SB, Sørensen LN, Malmgaard L et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 81(24), 13315–13324 (2007).
   PubMed Web of Science ®Google Scholar
• Baranek T, Manh TV, Alexandre Y et al. Differential responses of immune cells to type I interferon contribute to host resistance to viral infection. Cell Host Microbe 12(4), 571–584 (2012).
   PubMed Web of Science ®Google Scholar
• Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl Acad. Sci. USA 91(4), 1198–1205 (1994).
   PubMed Web of Science ®Google Scholar
• Kirkwood J. Cancer immunotherapy: the interferon-a experience. Semin. Oncol. 29(3 Suppl 7), 18–26 (2002).
   PubMed Web of Science ®Google Scholar
• Herberman RR, Ortaldo JR, Bonnard GD. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 277, 221–223 (1979).
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174(8), 4465–4469 (2005).
   PubMed Web of Science ®Google Scholar
• Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J. Biol. Chem. 271(41), 25479–25484 (1996).
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner D, Liu Y et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237–249 (2003).
   PubMed Web of Science ®Google Scholar
• Muller U, Steinhoff U, Reis LF et al. Functional role of type I and type II interferons in antiviral defense. Science 264(5167), 1918–1921 (1994).
   PubMed Web of Science ®Google Scholar
• Hwang SY, Hertzog PJ, Holland KA et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl Acad. Sci. USA 92(24), 11284–11288 (1995).
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon g-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95(13), 7556–7561 (1998).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6(7), 722–729 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez J, Huang X, Yang Y. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 180(3), 1592–1597 (2008).
   PubMed Web of Science ®Google Scholar
• Mizutani T, Neugebauer N, Putz EM et al. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. OncoImmunology 1(7), 0–10 (2012).
   Google Scholar
• Beuneu H, Deguine J, Bouvier I, Di Santo JP, Albert ML, Bousso P. Cutting Edge: A dual role for type I IFNs during polyinosinic-polycytidylic acid-induced NK cell activation. J. Immunol. 187(5), 2084–2088 (2011).
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Salazar-Mather TP, Dalod MY et al. Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169(8), 4279–4287 (2002).
   PubMed Web of Science ®Google Scholar
• Miyagi T, Takehara T, Nishio K et al. Altered interferon-a-signaling in natural natural killer (NK) from patients with chronic hepatitis C virus infection. J. Hepatol. 53(3), 424–430 (2010).
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15. Immunity 26(4), 503–517 (2007).
   PubMed Web of Science ®Google Scholar
• Boudreau JE, Stephenson KB, Wang F et al. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 71(7), 2497–2506 (2011).
   PubMed Web of Science ®Google Scholar
• Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G. Induction of interferon-g from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-a and tumour necrosis factor-a. Immunology 117(1), 38–46 (2006).
   PubMed Web of Science ®Google Scholar
• Mack EA, Kallal LE, Demers DA, Biron CA. Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection. MBio. 2(4), e00169-11 (2011).
   PubMedGoogle Scholar
• Zhu J, Huang X, Yang Y. A critical role for Type I IFN dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16(7), 1300–1307 (2008).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA 101(47), 16606–16611 (2004).
   PubMed Web of Science ®Google Scholar
• Dalod M, Salazar-Mather TP, Malmgaard L et al. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J. Exp. Med. 195(4), 517–528 (2002).
   PubMed Web of Science ®Google Scholar
• Hansen ML, Woetmann A, Krejsgaard T et al. IFN-α primes T-and NK-cells for IL-15-mediated signaling and cytotoxicity. Mol. Immunol. 48(15), 2087–2093 (2011).
   PubMed Web of Science ®Google Scholar
• Foong Y, Jans D, Rolph M, Gahan M, Mahalingam S. Interleukin-15 mediates potent antiviral responses via an interferon-dependent mechanism. Virology 393(2), 228–237 (2009).
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell-and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7(5), 507–516 (2006).
   PubMed Web of Science ®Google Scholar
• Teles RM, Graeber TG, Krutzik SR et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339(6126), 1448–1453 (2013).
   PubMed Web of Science ®Google Scholar
• Teijaro JR, Ng C, Lee AM et al. Persistent LCMV infection is controlled by blockade of Type I interferon signaling. Science 340(6129), 207–211 (2013).
   PubMed Web of Science ®Google Scholar
• Edlich B, Ahlenstiel G, Zabaleta AA et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55(1), 39–48 (2012).
   PubMed Web of Science ®Google Scholar
• Di Santo JP. Functionally distinct NK-cell subsets: Developmental origins and biological implications. Eur. J. Immunol. 38(11), 2948–2951 (2008).
   PubMed Web of Science ®Google Scholar
• Martínez-Rodríguez J, López-Botet M, Munteis E et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 141(3), 348–356 (2011).
   PubMed Web of Science ®Google Scholar
• Ahlenstiel G, Titerence RH, Koh C et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138(1), 325–335.e2 (2010).
   PubMed Web of Science ®Google Scholar
• Stegmann KA, Björkström NK, Veber H et al. Interferon-α-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138(5), 1885–1897. e10 (2010).
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137(3), 1151–1160, e7 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Morandi B, D’Agostino A et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur. J. Immunol. 33(2), 306–313 (2003).
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology 120(1), 73–82 (2007).
   PubMedGoogle Scholar
• Martín-Fontecha A, Thomsen LL, Brett S et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat. Immunol. 5(12), 1260–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Gao N, Dang T, Yuan D. IFN-γ-dependent and -independent initiation of switch recombination by NK cells. J. Immunol. 167(4), 2011–2018 (2001).
   PubMed Web of Science ®Google Scholar
• Abdul-Careem MF, Lee AJ, Pek EA et al. Genital HSV-2 infection induces short-term NK cell memory. PLoS ONE 7(3), e32821 (2012).
   Google Scholar
• Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 457(7229), 557–561 (2009).
   PubMed Web of Science ®Google Scholar
• Tovey MG, Lallemand C, Meritet J, Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 24, S46–S47, S2 (2006).
   Google Scholar
• Jego G, Palucka AK, Blanck J, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2), 225–234 (2003).
   PubMed Web of Science ®Google Scholar
• Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol. Immunother. 55(9), 1122–1131 (2006).
   PubMed Web of Science ®Google Scholar
• Bracci L, Canini I, Venditti M et al. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine 24, S56–S57, (2006).
   Google Scholar
• Long BR, Michaelsson J, Loo CP et al. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin. Vaccine Immunol. 15(1), 120–130 (2008).
   PubMedGoogle Scholar
• Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169(1), 375–383 (2002).
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Fletcher H, Porter D, Thompson F, Hill AV, Todryk SM. Comparing human T cell and NK cell responses in viral-based malaria vaccine trials. Vaccine 28(1), 21–27 (2009).
   PubMed Web of Science ®Google Scholar
• Ryan EJ, Harenberg A, Burdin N. The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by natural killer (NK) cells enhancing Th1 polarization. Vaccine 25(17), 3380–3390 (2007).
   PubMed Web of Science ®Google Scholar
• Jennings P, Yuan D. NK cell enhancement of antigen presentation by B lymphocytes. J. Immunol. 182(5), 2879–2887 (2009).
   PubMed Web of Science ®Google Scholar
• Newman KC, Korbel DS, Hafalla JC, Riley EM. Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-g responses to malaria. PLoS Pathog. 2(12), e118 (2006).
   PubMed Web of Science ®Google Scholar
• Gill N, Ashkar AA. Adaptive immune responses fail to provide protection against genital HSV-2 infection in the absence of IL-15. Eur. J. Immunol. 37(9), 2529–2538 (2007).
   PubMed Web of Science ®Google Scholar
• Kim M, Osborne NR, Zeng W et al. Herpes simplex virus antigens directly activate nk cells via tlr2, thus facilitating their presentation to CD4 T lymphocytes. J. Immunol. 188(9), 4158–4170 (2012).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fujii S. DC therapy induces long-term NK reactivity to tumors via host DC. Eur. J. Immunol. 39(2), 457–468 (2009).
   PubMed Web of Science ®Google Scholar
• Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J. Exp. Med. 208(2), 357–368 (2011).
   PubMed Web of Science ®Google Scholar
• Paust S, Gill HS, Wang B et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11(12), 1127–1135 (2010).
   PubMed Web of Science ®Google Scholar
• Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired immune responses: effector CD4 T cell-dependent activation of NK cells following vaccination. J. Immunol. 185(5), 2808–2818 (2010).
   PubMed Web of Science ®Google Scholar
• Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J. Exp. Med. 209(5), 947–954 (2012).
   PubMed Web of Science ®Google Scholar
• Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 128(2), 151–163 (2009).
   PubMed Web of Science ®Google Scholar